ADIAL PHARMACEUTICALS, INC. (ADIL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00688A3041
ADIAL PHARMACEUTICALS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -7.80 m USD |
| EBIT | -8.13 m USD |
| Net income | -7.98 m USD |
| Diluted EPS – continuing operations | -11.93 USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ADIAL PHARMACEUTICALS, INC.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
More stocks
- Premier Air Charter Holdings Inc. (PREM)
- AIBOTICS, INC. (AIBT)
- GRI Bio, Inc. (GRI)
- FARMHOUSE, INC. /NV (FMHS)
- Ernexa Therapeutics Inc. (ERNA)
- KwikClick, Inc. (KWIK)
- VACCINEX, INC. (VCNX)
- Medicus Pharma Ltd. (MDCX)
- Toppoint Holdings Inc. (TOPP)
- Dermata Therapeutics, Inc. (DRMA)
- AQUA POWER SYSTEMS INC. (APSI)
- PRINCETON CAPITAL CORP (PIAC)
Not investment advice. All data without warranty, price as of 04.11.2026. Details in the risk notice.